Do GLP-1s like liraglutide actually cut migraines in half?

What did @therealdrleemd actually say?

The creator claimed that liraglutide, a GLP-1 receptor agonist sold under brand names like Victoza and Saxenda, may reduce chronic migraines. Specifically, they said migraine days dropped "from 20 to 9" after three months of daily liraglutide, and that this happened "independent from weight loss." They then invited followers to DM them to become patients.

The transcript is garbled in places, likely a transcription artifact, but the core claim is clear enough: GLP-1 drugs might cut migraine frequency roughly in half, through some mechanism unrelated to shedding pounds. That's a genuinely interesting idea. The problem is how it was framed and what came after.

Does the science back this up?

Partially, but the evidence base is thin and the creator oversold it. The most relevant data comes from a small open-label pilot study by Ornello et al. (2021, Journal of Headache and Pain), which looked at liraglutide in patients with chronic migraine and obesity. Monthly migraine days did drop significantly, and some of that effect appeared to persist beyond what weight loss alone would explain. That part checks out.

But here's what the creator left out: the study enrolled a small number of participants, had no placebo control group, and was open-label, meaning patients knew what they were taking. That's a setup for substantial placebo effect, especially in migraine research where placebo response rates routinely hit 30 to 40 percent. A 2022 review by Papetti et al. in Frontiers in Neurology noted the mechanistic plausibility, citing GLP-1 receptors in the trigeminal system, but stopped well short of endorsing clinical use. The science is promising. It is not settled.

What did they get wrong (or right)?

Credit where it's due: the underlying hypothesis is real. GLP-1 receptors exist in brain regions involved in pain modulation, and there is a biologically plausible reason to think these drugs might affect migraine pathways beyond just reducing body weight. The creator got that right.

What they got wrong is the certainty. Saying migraine days drop "from 20 to 9" as if that's an established outcome misrepresents a single small pilot trial as though it were a landmark result. It is not. The trial was not randomized or blinded. The 55 percent reduction figure cannot be responsibly presented to a general audience as a likely outcome for any given patient.

• No mention of study size or design limitations
• No acknowledgment of placebo effect in migraine trials
• The invitation to DM for a prescription is a significant red flag on a social media platform

Recruiting patients through TikTok comments for off-label drug use, without any visible informed consent process visible to the public, is the part of this video that should concern regulators, not just fact-checkers.

What should you actually know?

If you have chronic migraines and are already on a GLP-1 agonist for diabetes or weight management, it is reasonable to ask your neurologist whether any changes in headache frequency seem worth tracking. That is a different conversation from seeking out liraglutide specifically to treat migraines.

Liraglutide is not approved by the FDA for migraine prevention. Using it off-label for that purpose is not inherently wrong, physicians make off-label decisions constantly, but it carries real risks: nausea, pancreatitis, thyroid concerns, and injection site reactions are all documented. Those risks need to be weighed against unproven migraine benefit in a proper clinical setting, not a DM thread.

If you want legitimate migraine prevention options, FDA-approved CGRP monoclonal antibodies like erenumab (Aimovig) and fremanezumab (Ajovy) have robust randomized trial data behind them. GLP-1s for migraines are nowhere near that evidentiary bar yet. Watch for ongoing trials, including NCT05998473, which is examining semaglutide in migraine populations. That data, when it arrives, will actually tell us something.